ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial

Darbepoetin alfa (DA) is used to treat anemia in lower-risk (IPSS low or int-1) myelodysplastic syndromes (MDS). However, whether mutations can predict the effectiveness of DA has not been examined. The present study aimed to determine predictive gene mutations. The primary endpoint was a correlatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Yasuyoshi, Nannya, Yasuhito, Ichikawa, Motoshi, Hanamoto, Hitoshi, Shibayama, Hirohiko, Maeda, Yoshinobu, Hata, Tomoko, Miyamoto, Toshihiro, Kawabata, Hiroshi, Takeuchi, Kazuto, Tanaka, Hiroko, Kishimoto, Junji, Miyano, Satoru, Matsumura, Itaru, Ogawa, Seishi, Akashi, Koichi, Kanakura, Yuzuru, Mitani, Kinuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588475/
https://www.ncbi.nlm.nih.gov/pubmed/35821550
http://dx.doi.org/10.1007/s12185-022-03414-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588475/
https://www.ncbi.nlm.nih.gov/pubmed/35821550
http://dx.doi.org/10.1007/s12185-022-03414-9

Ejemplares similares